New product newswire: January 22, 2007
Novartis Pharmaceuticals, East Hanover, N.J., (862) 778-8300, has received tentative approval for a new treatment option for patients with high blood pressure, although not for initial therapy. Exforge (valsartan and amlodipine besylate) will provide combination therapy in a single tablet made up of Novartis' Diovan and Pfizer's Norvasc.
RX
NEW DRUGS
Novartis Pharmaceuticals, East Hanover, N.J., (862) 778-8300, has received tentative approval for a new treatment option for patients with high blood pressure, although not for initial therapy. Exforge (valsartan and amlodipine besylate) will provide combination therapy in a single tablet made up of Novartis' Diovan and Pfizer's Norvasc.
BioSante Pharmaceuticals, Lincolnshire, Ill., (847) 478-0500, has received marketing approval for Bio-E-Gel (estradiol gel) in the United States. The product, approved in strengths of 0.87 gm per day and 1.7 gm per day, will carry the name Elestrin and will be marketed by Bradley Pharmaceuticals, Fairfield, N.J., (973) 882-1505, through its Kenwood Therapeutics Division. Elestrin, a topically applied gel, is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.
NEW FORMULATIONS
REINTRODUCTION
NEW INDICATION
FDA has granted to Merck & Co., Whitehouse Station, N.J., (908) 423-1000, a new indication for Invanz (ertapenem). The injectable antibiotic is now indicated to combat the surgical-site infections that can occur following elective colorectal surgery in adults. It is administered once daily.
